FDA Rejects Noven Fentanyl Patch ANDA Due To Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will cease reviewing Noven/Endo’s generic version of J&J’s Duragesic chronic pain therapy due to a higher drug content in the pending ANDA.